Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Oncol. Nov 10, 2013; 4(4): 82-84
Published online Nov 10, 2013. doi: 10.5306/wjco.v4.i4.82
Published online Nov 10, 2013. doi: 10.5306/wjco.v4.i4.82
Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?
Vera Hirsh, Division of Medical Oncology, McGill University Health Center, Quebec H3G 1A4, Canada
Author contributions: Hirsh V contributed to the personal view, evaluation of quality of life data.
Correspondence to: Vera Hirsh, MD, FRCP (C), Division of Medical Oncology, McGill University Health Center, 1650 Cedar Ave, Montreal, Quebec H3G 1A4, Canada. vera.hirsh@muhc.mcgill.ca
Telephone: +1-514-9341934 Fax: +1-514-9348379
Received: June 12, 2013
Revised: August 10, 2013
Accepted: September 18, 2013
Published online: November 10, 2013
Revised: August 10, 2013
Accepted: September 18, 2013
Published online: November 10, 2013
Core Tip
Core tip: Are the data on quality of life (QOL) and patient reported outcomes (PROs) from clinical trials of metastatic non-small-cell lung cancer important? Yes, they are important if the data of PROs and QOLs questionnaires are collected appropriately with a good patient’s compliance.